U.S. Markets closed

SpringWorks Therapeutics, Inc. (SWTX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
79.80+5.16 (+6.91%)
At close: 4:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close74.64
Open73.69
Bid34.22 x 800
Ask80.10 x 900
Day's Range73.04 - 85.63
52 Week Range19.50 - 85.63
Volume539,540
Avg. Volume325,445
Market Cap3.892B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-13.84
Earnings DateNov 12, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est83.20
  • SpringWorks Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
    GlobeNewswire

    SpringWorks Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference

    STAMFORD, Conn., Jan. 05, 2021 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that Saqib Islam, Chief Executive Officer, will present at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021 at 7:30 a.m. Eastern Standard Time. To access the live webcast of SpringWorks’ presentation, please visit the “Events & Presentations” page within the Investors & Media section of the company’s website at https://ir.springworkstx.com. A replay of the webcast will be available on SpringWorks’ website for a limited time following the conference.About SpringWorks Therapeutics SpringWorks is a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. SpringWorks has a differentiated portfolio of small molecule targeted oncology product candidates and is advancing two potentially registrational clinical trials in rare tumor types, as well as several other programs addressing highly prevalent, genetically defined cancers. SpringWorks’ strategic approach and operational excellence in clinical development have enabled it to rapidly advance its two lead product candidates into late-stage clinical trials while simultaneously entering into multiple shared-value partnerships with industry leaders to expand its portfolio. For more information, visit www.springworkstx.com and follow @SpringWorksTx on Twitter and LinkedIn.Contact: Kim Diamond Phone: 203-561-1646 Email: kdiamond@springworkstx.com

  • 10 Best Biotech Stocks to Invest In According To Billionaire Biotech Hedge Fund
    Insider Monkey

    10 Best Biotech Stocks to Invest In According To Billionaire Biotech Hedge Fund

    In this article, we will present the 10 best stocks to invest in according to the billionaire biotech hedge fund manager Joe Edelman. Click to skip ahead and see the 5 Best Biotech Stocks to Invest In. Joseph Edelman is one of the most successful biotech hedge fund portfolio managers since he founded Perceptive Advisors […]

  • Is SWTX A Good Stock To Buy Now?
    Insider Monkey

    Is SWTX A Good Stock To Buy Now?

    At Insider Monkey, we pore over the filings of nearly 817 top investment firms every quarter, a process we have now completed for the latest reporting period. The data we’ve gathered as a result gives us access to a wealth of collective knowledge based on these firms’ portfolio holdings as of September 30. In this […]